Morphoproteomic portrait of the mTOR pathway in mesenchymal chondrosarcoma.
Morphoproteomics is defined as the identification by immunohistochemistry of the molecular circuitry of various proteins in a tumor by noting their state of activation (translocation and phosphorylation) and correlative expressions. Such an approach can uncover or confirm potential molecular targets that may be essential to the growth, integrity, and histogenesis of a particular tumor type and that are amenable to specific therapeutic interventions. This communication illustrates the application of such an approach in depicting the mTOR pathway in mesenchymal chondrosarcoma.
Brown
Robert E
RE
Division of Laboratory Medicine, Geisinger Medical Center, Danville, PA 17822-0131, USA. rebrown@geisinger.edu
D014408:Biomarkers, Tumor / Q000378:metabolism; D019902:Chondrocytes / Q000378:metabolism / Q000473:pathology; D018211:Chondrosarcoma, Mesenchymal / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D011494:Protein Kinases / Q000378:metabolism*; D040901:Proteomics; D012983:Soft Tissue Neoplasms / Q000378:metabolism* / Q000473:pathology; D058570:TOR Serine-Threonine Kinases
D014408:Biomarkers, Tumor; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases